Eileen M. O’Reilly

Oct 25, 2024 | nature.com | Eileen M. O’Reilly

We read with interest the News & Views article by Nevala-Plagemann and Garrido-Laguna (Nevala-Plagemann, C. & Garrido-Laguna, I. NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Nat. Rev. Clin. Oncol. 21, 567–568 (2024))1. In this article, the authors question whether the addition of nanoliposomal irinotecan, 5-fluorouracil, leucovorin and oxaliplatin (NALIRIFOX) to therapeutic options constitutes true progress for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Jun 28, 2024 | nature.com | Linda Bojmar |Constantinos P. Zambirinis |Junbum Kim |Ankur Choubey |Jose Jessurun |Hakon Blomstrand | +21 more

AbstractMetastasis occurs frequently after resection of pancreatic cancer (PaC). In this study, we hypothesized that multi-parametric analysis of pre-metastatic liver biopsies would classify patients according to their metastatic risk, timing and organ site.

Apr 18, 2024 | nature.com | Bob Li |Eileen M. O’Reilly

AbstractRAS family variants—most of which involve KRAS—are the most commonly occurring hotspot mutations in human cancers and are associated with a poor prognosis. For almost four decades, KRAS has been considered undruggable, in part due to its structure, which lacks small-molecule binding sites. But recent developments in bioengineering, organic chemistry and related fields have provided the infrastructure to make direct KRAS targeting possible.

Oct 5, 2023 | nature.com | Eileen M. O’Reilly

AbstractPancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most lethal human malignancies. Much is known regarding the biology and pathophysiology of PDAC, but translating this knowledge to the clinic to improve patient outcomes has been challenging. In this Review, we discuss advances and practice-changing trials for PDAC.

May 13, 2023 | nature.com | Eileen M. O’Reilly

AbstractBackgroundWe sought to assess the influences of sleep duration, sleep adequacy, and daytime sleepiness on survival outcomes among Stage III colon cancer patients. MethodsWe conducted a prospective observational study of 1175 Stage III colon cancer patients enrolled in the CALGB/SWOG 80702 randomised adjuvant chemotherapy trial who completed a self-reported questionnaire on dietary and lifestyle habits 14–16 months post-randomisation.